Subcutaneous omalizumab + steroid vs placebo + steroid (stable steroid): Adverse event—serious 16 to 60 weeks
Subcutaneous omalizumab + steroid probably leads to lower adverse event—serious 16 to 60 weeks compared with placebo + steroid (stable steroid) (moderate certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Subcutaneous omalizumab + steroid vs placebo + steroid (stable steroid) Adverse event—serious 16 to 60 weeks · adults and children with asthma Subcutaneous omalizumab + steroid probably leads to lower adverse event—serious 16 to 60 weeks compared with placebo + steroid (stable steroid) (moderate certainty). Omalizumab for asthma in adults and children (2014) · Cochrane Headline outcomes only | OR 0.72 [0.57, 0.91] | 15 studies · 5713 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Omalizumab for asthma in adults and children 2014 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.